Talaris Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $76,477,000.
Profit Margin
| 2019 | 0 | -17.93M | |
|---|---|---|---|
| 2020 | 0 | -22.73M | |
| 2021 | 0 | -48.15M | |
| 2022 | 0 | -68.72M |
TALS Income Statement (2019 – 2022)
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
Revenue | ||||
Revenue | 0 | 0 | 0 | 0 |
Cost of revenue | 0 | 0 | 0 | 0 |
Gross profit | 0 | 0 | 0 | 0 |
Operating exp. | ||||
Research and development | 57.00M | 34.24M | 15.27M | 13.36M |
Selling and marketing | 0 | 0 | 0 | 0 |
Total operating expenses | 76.47M | 47.50M | 22.68M | 18.37M |
Operating income | -76.47M | -47.50M | -22.68M | -18.37M |
Other income (expenses), net | 2.58M | -326K | -23K | 223K |
Income before tax | -73.89M | -47.83M | -22.70M | -18.15M |
Income tax expense | -5.16M | 326K | 23K | -223K |
Net income | -68.72M | -48.15M | -22.73M | -17.93M |
Earnings per share | ||||
Basic EPS | -16.66 | -16.53 | -34 | -28.09 |
Diluted EPS | -16.66 | -16.53 | -34 | -28.09 |
| Data source | Data source |